Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
Type:
Application
Filed:
April 23, 2012
Publication date:
October 9, 2014
Applicant:
Myriad Genetics, Incorporated
Inventors:
Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
Type:
Application
Filed:
April 23, 2012
Publication date:
October 24, 2013
Applicant:
Myriad Genetics, Incorporated
Inventors:
Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
Abstract: The invention relates generally to methods of molecular analysis and particularly to methods of using genetic copy number variations and loss of heterozygosity in the characterization and treatment of disease.
Type:
Application
Filed:
February 24, 2011
Publication date:
March 28, 2013
Applicant:
Myriad Genetics, Incorporated
Inventors:
Victor Abkevich, Kirsten Timms, Alexander Gutin
Abstract: Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular detection and classification of disease are provided.
Type:
Application
Filed:
February 4, 2011
Publication date:
March 7, 2013
Applicant:
Myriad Genetics, Incorporated
Inventors:
Alexander Gutin, Srikanth Jammulapati, Susanne Wagner
Abstract: The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof.
Type:
Application
Filed:
September 10, 2010
Publication date:
January 3, 2013
Applicants:
Board of Regents of the University of Texas System, Myriad Genetics Incorporated
Inventors:
Steven Stone, Alexander Gutin, Darl Flake, Francisco J. Esteva, Dihua Yu
Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.
Type:
Application
Filed:
April 23, 2012
Publication date:
December 13, 2012
Applicants:
Myriad Genetics, Incorporated, Board of Regents, The University of Texas System
Inventors:
Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
June 20, 2011
Publication date:
January 19, 2012
Applicant:
Myriad Genetics, Incorporated
Inventors:
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Abstract: Variants in DPYD gene are disclosed which can result in abnormal synthesis of DPD proteins and alteration of DPD activities. The invention provides methods for detecting the newly discovered genetic variants. The DPD genetic variants of the invention can be used as biomarkers in predicting toxicity to 5-FU and other drugs metabolized by the DPD enzyme.
Abstract: The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.
Type:
Application
Filed:
December 20, 2002
Publication date:
March 31, 2011
Applicant:
Myriad Genetics, Incorporated
Inventors:
Adrian Hobden, Kenton Zavitz, Scott Morham
Abstract: Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells.
Type:
Application
Filed:
January 19, 2007
Publication date:
October 7, 2010
Applicant:
Myriad Genetics, Incorporated
Inventors:
Scott Morham, Kenton Zavitz, Adrian Hobden
Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.
Type:
Application
Filed:
April 1, 2010
Publication date:
July 29, 2010
Applicants:
Board of Regents, The University of Texas System, Myriad Genetics, Incorporated
Inventors:
Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
Abstract: A method for detecting large genomic rearrangements is disclosed, which is particularly useful in detecting deletions and duplications in the large genes such as BRCA1, BRCA2, MLH1 and MSH2.
Type:
Application
Filed:
May 18, 2009
Publication date:
February 11, 2010
Applicant:
Myriad Genetics, Incorporated
Inventors:
Thomas Scholl, Thaddeus Judkins, Brant Hendrickson, Benjamin Roa, Carrie Colvin